A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

New England Journal of Medicine
December 12, 2019 Vol. 381 No. 24
http://www.nejm.org/toc/nejm/medical-journal

 

Original Articles
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Both MAb114 and REGN-EB3 were superior to ZMapp in reducing mortality from EVD. Scientifically and ethically sound clinical research can be conducted during disease outbreaks and can help inform the outbreak response.
Sabue Mulangu, M.D., et al and the PALM Writing Group for the PALM Consortium Study Team